Skip to main content

Table 4 Association of the CRS score (CRS ≤ 20; CRS > 20) with NAT2 genotype stratified by gender.

From: A cross-sectional study of self-reported chemical-related sensitivity is associated with gene variants of drug-metabolizing enzymes

Gene

Genotype

CRS ≤ 20 n (%)

CRS > 20 n (%)

Univariate odds ratio (95% CIa)

Multivariateb odds ratio (95% CI)

P c

  

Females (n = 298)

NAT2 fast

*4/*4

9 (6.8)

7 (4.2)

1.00d

1.00d

 
 

*4/*5

40 (30.1)

30 (18.2)

0.96 (0.32–2.88)

0.97 (0.32–2.91)

0.958

 

*4/*6

24 (18.0)

22 (13.3)

1.18 (0.38–3.70)

1.18 (0.37–3.70)

0.780

 

*4/*7

2 (1.5)

3 (1.8)

1.93 (0.25–14.89)

2.01 (0.26–15.56)

0.505

NAT2 slow

*5/*5

19 (14.3)

35 (21.2)

2.37 (0.76–7.37)

2.38 (0.76–7.42)

0.136

 

*5/*6

29 (21.8)

43 (26.1)

1.91 (0.64–5.69)

1.93 (0.64–5.77)

0.241

 

*5/*7

2 (1.5)

3 (1.8)

1.93 (0.25–14.88)

1.92 (0.25–14.84)

0.533

 

*6/*6

8 (6.0)

21 (12.7)

3.38 (0.94–12.14)

3.44 (0.95–12.44)

0.059

 

*6/*7

-

1 (0.6)

n.c.e

n.c.e

-

 

*7/*7

-

-

-

-

-

NAT2 fast

all

75 (56.4)

62 (37.6)

1.00d

1.00d

 

NAT2 slow

all

58 (43.6)

103 (62.4)

2.15 (1.35–3.42)

2.16 (1.35–3.44)

0.001

  

Males (n = 223)

NAT2 fast

*4/*4

6 (5.2)

6 (5.6)

1.00d

1.00d

 
 

*4/*5

28 (24.3)

19 (17.6)

0.68 (0.19–2.42)

0.68 (0.19–2.52)

0.568

 

*4/*6

15 (13.0)

12 (11.1)

0.80 (0.20–3.13)

0.73 (0.18–2.95)

0.662

 

*4/*7

1 (0.9)

2 (1.9)

2.00 (0.14–28.41)

1.45 (0.10–21.03)

0.786

NAT2 slow

*5/*5

30 (26.1)

26 (24.1)

0.87 (0.25–3.02)

0.93 (0.26–3.34)

0.905

 

*5/*6

27 (23.5)

31 (28.7)

1.15 (0.33–3.98)

1.18 (0.33–4.24)

0.798

 

*5/*7

2 (1.7)

2 (1.9)

1.00 (0.10–9.61)

0.95 (0.09–9.65)

0.963

 

*6/*6

6 (5.2)

10 (9.3)

1.67 (0.37–7.61)

1.61 (0.33–7.76)

0.555

 

*6/*7

-

-

-

-

-

 

*7/*7

-

-

-

-

-

NAT2 fast

all

50 (43.5)

39 (36.1)

1.00d

1.00d

 

NAT2 slow

all

65 (56.5)

69 (63.9)

1.36 (0.79–2.33)

1.45 (0.82–2.56)

0.199